January 12, 2024 09:58 AM EST
News Briefing

Ji Xing buys Bio­gen’s acute is­chemic stroke drug; Ex­elix­is/BioIn­vent part­ner­ship ends; Clin­Choice's deal in SEA

Jaimy Lee

Deputy Editor

Anna Brown

News Reporter

Ji Xing ac­quires Bio­gen’s ex­per­i­men­tal ther­a­py for acute is­chemic stroke: The Shang­hai-based bio­phar­ma did not dis­close the fi­nan­cial terms of the deal. Back in 2018 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times